thyroxine has been researched along with Osteoporosis in 106 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both thyroid dysfunction and levothyroxine (LT4) therapy have been associated with bone loss, but studies on the effect of LT4 for subclinical hypothyroidism (SHypo) on bone yielded conflicting results." | 9.34 | Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study. ( Aeberli, D; Bauer, DC; Blum, MR; Collet, TH; Del Giovane, C; Feller, M; Gonzalez Rodriguez, E; Gussekloo, J; Hans, D; Kearney, PM; Löwe, AL; Mooijaart, S; Rodondi, N; Stott, DJ; Stuber, M; van Heemst, D; van Vliet, NA; Westendorp, RGJ, 2020) |
| "The effect of subclinical hyperthyroidism on bone mineral density is controversial and could be significant in patients with differentiated thyroid carcinoma who receive suppressive doses of levothyroxine (LT4)." | 9.11 | Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. ( Alonso, N; Granada, ML; Holgado, S; Reverter, JL; Salinas, I; Sanmartí, A, 2005) |
| " The fracture risk increases in cases of untreated thyrotoxicosis, when administered suppressive doses of thyroxine, in postmenopausal women and patients with low peak bone mass." | 8.80 | [The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis]. ( Bolanowski, M; Zatońska, K, 2000) |
| "L-Thyroxine (L-T4) in the treatment of thyroid disease resulting in reduced serum thyrotropin (TSH) has been associated with reduced bone mass and thus the potential risk of premature development of osteoporosis." | 8.79 | Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. ( Faber, J; Galløe, AM, 1994) |
| " However, conflicting results were observed regarding the association between levothyroxine treatment and osteoporosis risk." | 8.12 | Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. ( Almutairi, A; Alolaiwi, LA; Alotaibe, HF; Alotaibi, HF; Alsubaie, N; Badri, M; Balaha, MF; Khafagy, ES, 2022) |
| "Our population-based cohort study showed that thyroid cancer patients receiving levothyroxine have a higher risk of osteoporosis." | 7.88 | Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. ( Chen, HT; Kao, CH; Lin, CL; Lin, SY, 2018) |
| "Excessive TSH suppression contributed to the secondary osteoporosis in this patient; BMD normalized after dose reduction of levothyroxine and no fractures occurred during 23 years' follow-up." | 7.85 | Case report: fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up. ( Laine, CM; Landin-Wilhelmsen, K, 2017) |
| "While further studies are needed, physicians should be concerned about potential levothyroxine overtreatment in elderly osteoporosis patients." | 7.80 | Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. ( Choi, NK; Kim, JY; Ko, YJ; Lee, J; Park, BJ; Song, HJ, 2014) |
| "To determine bone mineral density in patients with differentiated thyroid carcinoma receiving thyroxine replacement therapy in suppressive doses, we studied 65 patients (47 women and 18 men; age 25-83 years, mean+/-SD 52." | 7.69 | Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. ( Görres, G; Götze, M; Kaim, A; Müller-Brand, J; Otte, A, 1996) |
| "Overt hyperthyroidism, defined as suppressed thyrotropin (previously thyroid-stimulating hormone) and high concentration of triiodothyronine (T3) and/or free thyroxine (FT4), affects approximately 0." | 5.41 | Hyperthyroidism: A Review. ( Lee, SY; Pearce, EN, 2023) |
| "Both thyroid dysfunction and levothyroxine (LT4) therapy have been associated with bone loss, but studies on the effect of LT4 for subclinical hypothyroidism (SHypo) on bone yielded conflicting results." | 5.34 | Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study. ( Aeberli, D; Bauer, DC; Blum, MR; Collet, TH; Del Giovane, C; Feller, M; Gonzalez Rodriguez, E; Gussekloo, J; Hans, D; Kearney, PM; Löwe, AL; Mooijaart, S; Rodondi, N; Stott, DJ; Stuber, M; van Heemst, D; van Vliet, NA; Westendorp, RGJ, 2020) |
| " We report a case in which exogenous L-thyroxine side effect on bone in the treatment of thyroid solitary nodule disease produced bone loss in a patient with subclinical hyperparathyroidism due to an ectopic parathyroid adenoma." | 5.30 | An ectopic parathyroid adenoma revealed by L-thyroxine side effect on bone. Case report. ( Cavallaro, A; Paggi, A; Trimarchi, CP, 1997) |
| "The effect of subclinical hyperthyroidism on bone mineral density is controversial and could be significant in patients with differentiated thyroid carcinoma who receive suppressive doses of levothyroxine (LT4)." | 5.11 | Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. ( Alonso, N; Granada, ML; Holgado, S; Reverter, JL; Salinas, I; Sanmartí, A, 2005) |
| "The aim of this work was to evaluate the degree of bone resorption and incidence of osteoporosis in female postmenopausal patients with differentiated thyroid cancer treated with suppressive doses of thyroxine." | 5.09 | [Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine]. ( August, R; Bartnikowa, W; Czernik, E; Deja, R; Handkiewicz-Junak, D; Jurecka-Tuleja, B; Kukulska, A, 2001) |
| " Established thyrotoxicosis has long been recognised as a cause of high bone turnover osteoporosis and fracture but more recent studies have suggested that subclinical hyperthyroidism and long-term suppressive doses of thyroxine (T4) may also result in decreased bone mineral density (BMD) and an increased risk of fragility fracture, particularly in postmenopausal women." | 4.88 | The skeletal consequences of thyrotoxicosis. ( Bassett, JH; Brassill, MJ; Nicholls, JJ; Williams, GR, 2012) |
| "Patients with differentiated thyroid carcinoma are commonly treated long-term with thyrotropin (TSH)-suppressive thyroxine replacement therapy, which lead to a state of subclinical hyperthyroidism." | 4.84 | [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma]. ( Miyakawa, M, 2007) |
| " The fracture risk increases in cases of untreated thyrotoxicosis, when administered suppressive doses of thyroxine, in postmenopausal women and patients with low peak bone mass." | 4.80 | [The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis]. ( Bolanowski, M; Zatońska, K, 2000) |
| "L-Thyroxine (L-T4) in the treatment of thyroid disease resulting in reduced serum thyrotropin (TSH) has been associated with reduced bone mass and thus the potential risk of premature development of osteoporosis." | 4.79 | Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. ( Faber, J; Galløe, AM, 1994) |
| "Long-term use of L-Thyroxine (LT4), the synthetic thyroxine hormone used for thyroid hormone replacement therapy, is an important risk factor for osteoporosis." | 4.31 | Evaluation of cortical and trabecular bone structure of the mandible in patients using L-Thyroxine. ( Erturk, M; Gulec, M; Tassoker, M, 2023) |
| " However, conflicting results were observed regarding the association between levothyroxine treatment and osteoporosis risk." | 4.12 | Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. ( Almutairi, A; Alolaiwi, LA; Alotaibe, HF; Alotaibi, HF; Alsubaie, N; Badri, M; Balaha, MF; Khafagy, ES, 2022) |
| "Our population-based cohort study showed that thyroid cancer patients receiving levothyroxine have a higher risk of osteoporosis." | 3.88 | Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. ( Chen, HT; Kao, CH; Lin, CL; Lin, SY, 2018) |
| "Excessive TSH suppression contributed to the secondary osteoporosis in this patient; BMD normalized after dose reduction of levothyroxine and no fractures occurred during 23 years' follow-up." | 3.85 | Case report: fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up. ( Laine, CM; Landin-Wilhelmsen, K, 2017) |
| "While further studies are needed, physicians should be concerned about potential levothyroxine overtreatment in elderly osteoporosis patients." | 3.80 | Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. ( Choi, NK; Kim, JY; Ko, YJ; Lee, J; Park, BJ; Song, HJ, 2014) |
| " In the first group L-thyroxine-induced hyperthyroid rats were ovariectomized (OVX) while the OVX rats were administered L-thyroxine in the second group." | 3.73 | Bone metabolism in ovariectomized rats with induced hyperthyroidism: the effect of estrogen replacement. ( Aydin, S; Guner, I; Karter, Y; Kaya, S; Simsek, C; Simsek, G; Sozer, V; Uzun, H; Yigit, G; Yucel, R, 2006) |
| "Pain intensity was graded according to 4-score scale, atraumatic fractures in the past were recorded, mineral bone density (MBD) was studied, TTH and T4 levels and biochemical indices of calcium-phosphorus and bone metabolism were studied, thyroid volume was calculated by J." | 3.73 | [Features of osteopenic syndrome in diffuse toxic goiter]. ( Davydova, LI; Nekrasova, MR; Suplotova, LA, 2005) |
| "To determine whether long-term thyroxine therapy in the premenopausal period is a risk factor for the development of secondary osteoporosis and whether women receiving this therapy have increased bone loss during the premenopausal period." | 3.71 | Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. ( Karner, I; Sijanovic, S, 2001) |
| " Prolonged subclinical hyperthyroidism due to L-thyroxine treatment has been associated with reduced bone mass and thus with the potential risk of premature development of osteoporosis." | 3.70 | Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. ( Carpinelli, A; Del Puente, AE; Esposito Del Puente, A; Lupoli, G; Nuzzo, V; Oriente, P; Rampone, E, 1998) |
| "To determine bone mineral density in patients with differentiated thyroid carcinoma receiving thyroxine replacement therapy in suppressive doses, we studied 65 patients (47 women and 18 men; age 25-83 years, mean+/-SD 52." | 3.69 | Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma. ( Görres, G; Götze, M; Kaim, A; Müller-Brand, J; Otte, A, 1996) |
| "These negative findings, that thyroxine in suppressive doses does not significantly reduce bone mineral density in New Zealand patients suggest that thyroxine therapy alone is not a major risk factor for the development of osteoporosis." | 3.68 | Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. ( Ayling, EM; Brownlie, BE; Elliot, JR; Florkowski, CM; Turner, JG, 1993) |
| "Subclinical hyperthyroidism has been associated with increased risk of atrial fibrillation and osteoporosis, but the association with cardiovascular disease and death is uncertain." | 2.72 | Decision Making in Subclinical Thyroid Disease. ( Evron, JM; Papaleontiou, M, 2021) |
| "Osteoporosis is a skeletal disorder characterized by decreased mass and compromised bone strength predisposing to an increased risk of fractures." | 2.52 | Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. ( Canalis, E; Mirza, F, 2015) |
| "Drug-induced osteoporosis is common and has a significant impact on the prognosis of patients suffering from chronic debilitating diseases." | 2.46 | Drug-induced osteoporosis: mechanisms and clinical implications. ( Canalis, E; Giustina, A; Mazziotti, G, 2010) |
| "Early diagnosis of osteoporosis has also substantial importance." | 2.40 | [The influence of thyroid diseases and their treatment on the development of osteoporosis]. ( Ciesielska-Kopacz, N; Kos-Kudła, B; Pluskiewicz, W, 1998) |
| "In the setting of differentiated thyroid cancer (DTC) management, < 0." | 1.42 | Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer. ( Do Cao, C; Wémeau, JL, 2015) |
| "Despite similar rates of recurrence (HR 1." | 1.42 | Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. ( Boucai, L; Fagin, JA; Ganly, I; Mahrous, A; Nixon, IJ; Palmer, FL; Patel, SG; Smith, AW; Tuttle, RM; Wang, LY, 2015) |
| "Myxedema coma (MC) is a rare, but often fatal endocrine emergency." | 1.37 | A case of myxedema coma caused by isolated thyrotropin stimulating hormone deficiency and Hashimoto's thyroiditis. ( Chihara, K; Hino, Y; Iida, K; Ohara, T, 2011) |
| "Although osteoporosis is increasingly shown to occur in a considerable proportion of men, data on risk factors for male osteoporosis are limited." | 1.36 | The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men. ( Bae, SJ; Choe, JW; Kim, BJ; Kim, GS; Kim, HK; Kim, HY; Koh, JM; Lee, SH, 2010) |
| "Intense bone resorption is a natural phenomenon also observed in some teleosts, during reproductive migration and fasting." | 1.34 | Thyroid hormone-induced demineralisation of the vertebral skeleton of the eel, Anguilla anguilla. ( Aroua, S; Baloche, S; Dufour, S; Kacem, A; Lopez, E; Meunier, F; Rousseau, K; Sbaihi, M, 2007) |
| " The dangers associated with changing to a preparation with different bioavailability are summarized, noting the particular danger of giving a more active preparation to a patient receiving TSH-suppressive doses of levothyroxine." | 1.33 | New questions regarding bioequivalence of levothyroxine preparations: a clinician's response. ( Green, WL, 2005) |
| "Hyperthyroidism is characterized by increased bone turnover and resorptive activity." | 1.32 | Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism. ( Aydin, S; Karter, Y; Simsek, G; Uzun, H, 2003) |
| " We report a case in which exogenous L-thyroxine side effect on bone in the treatment of thyroid solitary nodule disease produced bone loss in a patient with subclinical hyperparathyroidism due to an ectopic parathyroid adenoma." | 1.30 | An ectopic parathyroid adenoma revealed by L-thyroxine side effect on bone. Case report. ( Cavallaro, A; Paggi, A; Trimarchi, CP, 1997) |
| " Thyroxine dosage was reduced by 25 or 50 micrograms of L-thyroxine and patients were reviewed six months later." | 1.29 | Feasibility of reducing L-thyroxine dose in patients with a suppressed serum TSH. ( Browning, MC; Jung, RT; Leese, GP, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (10.38) | 18.7374 |
| 1990's | 28 (26.42) | 18.2507 |
| 2000's | 34 (32.08) | 29.6817 |
| 2010's | 26 (24.53) | 24.3611 |
| 2020's | 7 (6.60) | 2.80 |
| Authors | Studies |
|---|---|
| Evron, JM | 1 |
| Papaleontiou, M | 1 |
| Alotaibe, HF | 1 |
| Alolaiwi, LA | 1 |
| Almutairi, A | 1 |
| Alsubaie, N | 1 |
| Badri, M | 1 |
| Balaha, MF | 1 |
| Khafagy, ES | 1 |
| Alotaibi, HF | 1 |
| Lee, SY | 1 |
| Pearce, EN | 1 |
| Gulec, M | 1 |
| Tassoker, M | 1 |
| Erturk, M | 1 |
| Gonzalez Rodriguez, E | 1 |
| Stuber, M | 1 |
| Del Giovane, C | 1 |
| Feller, M | 1 |
| Collet, TH | 1 |
| Löwe, AL | 1 |
| Blum, MR | 1 |
| van Vliet, NA | 1 |
| van Heemst, D | 1 |
| Kearney, PM | 1 |
| Gussekloo, J | 1 |
| Mooijaart, S | 1 |
| Westendorp, RGJ | 1 |
| Stott, DJ | 1 |
| Aeberli, D | 1 |
| Bauer, DC | 1 |
| Hans, D | 1 |
| Rodondi, N | 1 |
| Deng, T | 1 |
| Zhang, W | 1 |
| Zhang, Y | 1 |
| Zhang, M | 1 |
| Huan, Z | 1 |
| Yu, C | 1 |
| Zhang, X | 1 |
| Wang, Y | 2 |
| Xu, J | 1 |
| Sousa, BÉCA | 1 |
| Silva, BC | 1 |
| de Oliveira Guidotti, T | 1 |
| Pires, MC | 1 |
| Soares, MMS | 1 |
| Kakehasi, AM | 1 |
| Laine, CM | 1 |
| Landin-Wilhelmsen, K | 1 |
| Ilias, I | 1 |
| Venaki, E | 1 |
| Nikopoulou, S | 1 |
| Koch, CA | 1 |
| Lin, SY | 1 |
| Lin, CL | 1 |
| Chen, HT | 1 |
| Kao, CH | 1 |
| Kim, K | 1 |
| Kim, IJ | 1 |
| Pak, K | 1 |
| Kim, SJ | 1 |
| Shin, S | 1 |
| Kim, BH | 1 |
| Kim, SS | 1 |
| Lee, BJ | 1 |
| Jeon, YK | 1 |
| Ko, YJ | 1 |
| Kim, JY | 2 |
| Lee, J | 1 |
| Song, HJ | 1 |
| Choi, NK | 1 |
| Park, BJ | 1 |
| Acibucu, F | 1 |
| Kilicli, F | 1 |
| Dokmetas, HS | 1 |
| Williams, GR | 3 |
| Cardoso, LF | 1 |
| Maciel, LM | 1 |
| Paula, FJ | 1 |
| Wang, LY | 1 |
| Smith, AW | 1 |
| Palmer, FL | 1 |
| Tuttle, RM | 1 |
| Mahrous, A | 1 |
| Nixon, IJ | 1 |
| Patel, SG | 1 |
| Ganly, I | 1 |
| Fagin, JA | 1 |
| Boucai, L | 1 |
| Mirza, F | 1 |
| Canalis, E | 2 |
| Do Cao, C | 1 |
| Wémeau, JL | 1 |
| Acar, B | 1 |
| Ozay, AC | 1 |
| Ozay, OE | 1 |
| Okyay, E | 1 |
| Sisman, AR | 1 |
| Ozaksoy, D | 1 |
| Villani, ER | 1 |
| Onder, G | 1 |
| Carfì, A | 1 |
| Di Segni, C | 1 |
| Raimondo, S | 1 |
| Silvestrini, A | 1 |
| Meucci, E | 1 |
| Mancini, A | 1 |
| Oheim, R | 1 |
| Simon, MJK | 1 |
| Steiner, M | 1 |
| Vettorazzi, E | 1 |
| Barvencik, F | 1 |
| Ignatius, A | 1 |
| Amling, M | 1 |
| Clarke, IJ | 1 |
| Pogoda, P | 1 |
| Beil, FT | 1 |
| de Rougemont, A | 1 |
| Mourot, MG | 1 |
| Riou, JP | 1 |
| Bros, JA | 1 |
| Lluís, PG | 1 |
| Cabot, GL | 1 |
| Pedragós, AC | 1 |
| Svare, A | 1 |
| Nilsen, TI | 1 |
| Bjøro, T | 1 |
| Forsmo, S | 1 |
| Schei, B | 1 |
| Langhammer, A | 1 |
| Pfeilschifter, J | 1 |
| Flynn, RW | 1 |
| Bonellie, SR | 1 |
| Jung, RT | 2 |
| MacDonald, TM | 1 |
| Morris, AD | 1 |
| Leese, GP | 2 |
| Heumüller, R | 1 |
| Kretschmer, I | 1 |
| Döhler, N | 1 |
| Wittich, R | 1 |
| Menzen, M | 1 |
| Homann, J | 1 |
| Jaehde, U | 1 |
| Kim, BJ | 1 |
| Lee, SH | 1 |
| Bae, SJ | 1 |
| Kim, HK | 1 |
| Choe, JW | 1 |
| Kim, HY | 1 |
| Koh, JM | 1 |
| Kim, GS | 1 |
| Reverter, JL | 2 |
| Colomé, E | 1 |
| Puig Domingo, M | 1 |
| Julián, T | 1 |
| Halperin, I | 1 |
| Sanmartí, A | 2 |
| Mazziotti, G | 1 |
| Giustina, A | 1 |
| Iida, K | 1 |
| Hino, Y | 1 |
| Ohara, T | 1 |
| Chihara, K | 1 |
| Segal, E | 1 |
| Hochberg, I | 1 |
| Weisman, Y | 1 |
| Ish-Shalom, S | 1 |
| Bours, SP | 1 |
| van Geel, TA | 1 |
| Geusens, PP | 1 |
| Janssen, MJ | 1 |
| Janzing, HM | 1 |
| Hoffland, GA | 1 |
| Willems, PC | 1 |
| van den Bergh, JP | 1 |
| Medici, M | 1 |
| Rivadeneira, F | 1 |
| van der Deure, WM | 1 |
| Hofman, A | 1 |
| van Meurs, JB | 1 |
| Styrkársdottir, U | 1 |
| van Duijn, CM | 1 |
| Spector, T | 1 |
| Kiel, DP | 1 |
| Uitterlinden, AG | 1 |
| Visser, TJ | 1 |
| Peeters, RP | 1 |
| Cooper, DS | 1 |
| Biondi, B | 2 |
| Nicholls, JJ | 1 |
| Brassill, MJ | 1 |
| Bassett, JH | 2 |
| Baliram, R | 2 |
| Sun, L | 2 |
| Cao, J | 1 |
| Li, J | 1 |
| Latif, R | 2 |
| Huber, AK | 1 |
| Yuen, T | 1 |
| Blair, HC | 1 |
| Zaidi, M | 2 |
| Davies, TF | 2 |
| Łacka, K | 1 |
| Jurecka-Tuleja, B | 1 |
| August, R | 1 |
| Kukulska, A | 1 |
| Bartnikowa, W | 1 |
| Deja, R | 1 |
| Czernik, E | 1 |
| Handkiewicz-Junak, D | 1 |
| Jastrzebska, H | 1 |
| Gietka-Czernel, M | 1 |
| Zgliczyński, S | 1 |
| POTTON, F | 1 |
| DESSIMOND, JL | 1 |
| SPENCE, AW | 1 |
| Simsek, G | 3 |
| Uzun, H | 3 |
| Karter, Y | 3 |
| Aydin, S | 3 |
| Yigit, G | 2 |
| Chae, HJ | 2 |
| Chae, SW | 1 |
| Yun, DH | 2 |
| Keum, KS | 1 |
| Yoo, SK | 2 |
| Kim, HR | 2 |
| Chin, HY | 1 |
| Kim, HM | 1 |
| Kim, SB | 1 |
| Palmieri, EA | 1 |
| Klain, M | 1 |
| Schlumberger, M | 1 |
| Filetti, S | 1 |
| Lombardi, G | 1 |
| Heijckmann, AC | 1 |
| Huijberts, MS | 1 |
| Geusens, P | 1 |
| de Vries, J | 1 |
| Menheere, PP | 1 |
| Wolffenbuttel, BH | 1 |
| Clarke, N | 1 |
| Kabadi, UM | 1 |
| Green, WL | 1 |
| Nekrasova, MR | 1 |
| Suplotova, LA | 1 |
| Davydova, LI | 1 |
| Holgado, S | 1 |
| Alonso, N | 1 |
| Salinas, I | 1 |
| Granada, ML | 1 |
| Naessén, S | 1 |
| Carlström, K | 1 |
| Glant, R | 1 |
| Jacobsson, H | 1 |
| Hirschberg, AL | 1 |
| Sbaihi, M | 1 |
| Kacem, A | 1 |
| Aroua, S | 1 |
| Baloche, S | 1 |
| Rousseau, K | 1 |
| Lopez, E | 1 |
| Meunier, F | 1 |
| Dufour, S | 1 |
| Sampath, TK | 1 |
| Simic, P | 1 |
| Sendak, R | 2 |
| Draca, N | 1 |
| Bowe, AE | 1 |
| O'Brien, S | 1 |
| Schiavi, SC | 1 |
| McPherson, JM | 1 |
| Vukicevic, S | 2 |
| Sozer, V | 1 |
| Guner, I | 1 |
| Yucel, R | 1 |
| Simsek, C | 1 |
| Kaya, S | 1 |
| Mohammadi, B | 1 |
| Haghpanah, V | 1 |
| Tavangar, SM | 1 |
| Larijani, B | 1 |
| Miyakawa, M | 1 |
| Yang, G | 1 |
| McPherson, J | 1 |
| Zhu, LL | 1 |
| Iqbal, J | 1 |
| Natrajan, A | 1 |
| Arabi, A | 1 |
| Yamoah, K | 1 |
| Moonga, BS | 1 |
| Gabet, Y | 1 |
| Bab, I | 1 |
| Abe, E | 1 |
| Sampath, K | 1 |
| Briot, K | 1 |
| Roux, C | 1 |
| Frost, HM | 1 |
| Wolinsky-Friedland, M | 1 |
| Wartofsky, L | 1 |
| Baran, DT | 2 |
| Marcocci, C | 1 |
| Golia, F | 1 |
| Bruno-Bossio, G | 1 |
| Vignali, E | 1 |
| Pinchera, A | 1 |
| Faber, J | 1 |
| Galløe, AM | 1 |
| Audran, M | 1 |
| Florkowski, CM | 1 |
| Brownlie, BE | 1 |
| Elliot, JR | 1 |
| Ayling, EM | 1 |
| Turner, JG | 1 |
| Ongphiphadhanakul, B | 1 |
| Jenis, LG | 1 |
| Braverman, LE | 1 |
| Alex, S | 1 |
| Stein, GS | 1 |
| Lian, JB | 1 |
| Földes, J | 2 |
| Tarján, G | 1 |
| Szathmari, M | 1 |
| Varga, F | 1 |
| Krasznai, I | 1 |
| Horvath, C | 1 |
| Wimalawansa, SJ | 2 |
| Banks, LM | 1 |
| Görres, G | 1 |
| Kaim, A | 1 |
| Otte, A | 1 |
| Götze, M | 1 |
| Müller-Brand, J | 1 |
| Browning, MC | 1 |
| Lakatos, P | 1 |
| Gyulai, L | 1 |
| Jaggi, J | 1 |
| Bauer, MS | 1 |
| Younkin, S | 1 |
| Rubin, L | 1 |
| Attie, M | 1 |
| Whybrow, PC | 1 |
| Paggi, A | 1 |
| Trimarchi, CP | 1 |
| Cavallaro, A | 1 |
| Wu, H | 1 |
| Zhou, J | 1 |
| Ciesielska-Kopacz, N | 1 |
| Kos-Kudła, B | 1 |
| Pluskiewicz, W | 1 |
| Nuzzo, V | 1 |
| Lupoli, G | 1 |
| Esposito Del Puente, A | 1 |
| Rampone, E | 1 |
| Carpinelli, A | 1 |
| Del Puente, AE | 1 |
| Oriente, P | 1 |
| Zeni, SN | 1 |
| Gómez Acotto, C | 1 |
| Di Gregorio, S | 1 |
| Wimalawansa, SM | 1 |
| Gruber, DM | 1 |
| Huber, JC | 1 |
| Zatońska, K | 1 |
| Bolanowski, M | 1 |
| Aĭlamazian, EK | 1 |
| Kornilov, NV | 1 |
| Avrunin, AS | 1 |
| Sukhanova, AM | 1 |
| Zazerskaia, IE | 1 |
| Al-Abadi, AC | 1 |
| Mikosch, P | 1 |
| Jauk, B | 1 |
| Gallowitsch, HJ | 1 |
| Pipam, W | 1 |
| Kresnik, E | 1 |
| Lind, P | 1 |
| Toft, AD | 1 |
| Sijanovic, S | 1 |
| Karner, I | 1 |
| Kitahama, S | 1 |
| Wada, S | 1 |
| Delcambre, B | 1 |
| Franklyn, JA | 2 |
| Betteridge, J | 1 |
| Daykin, J | 1 |
| Holder, R | 1 |
| Oates, GD | 1 |
| Parle, JV | 1 |
| Lilley, J | 1 |
| Heath, DA | 1 |
| Sheppard, MC | 3 |
| Falch, JA | 1 |
| Baxter, MA | 1 |
| Ding, G | 1 |
| Jancar, J | 1 |
| Ataya, K | 1 |
| Mercado, A | 1 |
| Kartaginer, J | 1 |
| Abbasi, A | 1 |
| Moghissi, KS | 1 |
| Krølner, B | 1 |
| Fraser, SA | 1 |
| Anderson, JB | 1 |
| Smith, DA | 1 |
| Wilson, GM | 1 |
| Bénichou, C | 1 |
| Méry, C | 1 |
| Raisz, LG | 1 |
| Bingham, PJ | 1 |
| Twrdy, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial[NCT01660126] | Phase 4 | 737 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment[NCT02491008] | Phase 4 | 145 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.[NCT01739972] | 180 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
30 reviews available for thyroxine and Osteoporosis
| Article | Year |
|---|---|
Decision Making in Subclinical Thyroid Disease.
Topics: Age Factors; Atrial Fibrillation; Cardiovascular Diseases; Clinical Decision-Making; Cognition Disor | 2021 |
Hyperthyroidism: A Review.
Topics: Adult; Antithyroid Agents; Female; Graves Disease; Humans; Hyperthyroidism; Iodine; Iodine Radioisot | 2023 |
The multiple effects of thyroid disorders on bone and mineral metabolism.
Topics: Animals; Bone and Bones; Calcification, Physiologic; Calcium; Databases, Bibliographic; Epiphyses; H | 2014 |
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.
Topics: Acromegaly; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Autoimmune Diseases; Celiac Disea | 2015 |
[Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy].
Topics: Adult; Atrial Fibrillation; Autoimmune Diseases; Comorbidity; Contraindications; Dose-Response Relat | 2011 |
Drug-induced osteoporosis: mechanisms and clinical implications.
Topics: Androgen Antagonists; Anti-Retroviral Agents; Aromatase Inhibitors; Bone Density; Calcineurin Inhibi | 2010 |
Subclinical thyroid disease.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Comorbidity; Diagnosis, Differential; Disease Progress | 2012 |
The skeletal consequences of thyrotoxicosis.
Topics: Bone Density; Fractures, Bone; Humans; Hyperthyroidism; Hypothalamo-Hypophyseal System; Models, Biol | 2012 |
[Treatment with L-thyroxine for differentiated thyroid carcinoma].
Topics: Cardiovascular Diseases; Humans; Osteoporosis; Thyroid Neoplasms; Thyrotropin; Thyroxine | 2001 |
[Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
Topics: Administration, Cutaneous; Administration, Oral; Estrogens; Female; Hormone Replacement Therapy; Hum | 2001 |
The molecular actions of thyroid hormone in bone.
Topics: Adolescent; Adult; Animals; Bone and Bones; Bone Density; Chondrocytes; Female; Humans; Mice; Mice, | 2003 |
Subclinical hyperthyroidism: clinical features and treatment options.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Cardiovascular Diseases; Female; Humans; Hyperthyroid | 2005 |
Optimizing treatment of hypothyroidism.
Topics: Aged; Aging; Coronary Disease; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Femal | 2004 |
[Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Topics: Atrial Fibrillation; Chemotherapy, Adjuvant; Humans; Hyperthyroidism; Neoplasm Recurrence, Local; Os | 2007 |
Drug-induced osteoporosis: beyond glucocorticoids.
Topics: Aromatase Inhibitors; Bone Remodeling; Estrogens; Female; Glucocorticoids; Gonadotropin-Releasing Ho | 2008 |
The skeletal intermediary organization.
Topics: Bone and Bones; Bone Development; Bone Diseases; Bone Resorption; Cell Differentiation; Cell Divisio | 1983 |
Drug-induced metabolic bone disease.
Topics: Caffeine; Female; Glucocorticoids; Heparin; Humans; Hypothyroidism; Male; Middle Aged; Osteoporosis; | 1995 |
Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
Topics: Adult; Bone Density; Cross-Sectional Studies; Female; Femur; Humans; Hyperthyroidism; Hypothyroidism | 1994 |
[Iatrogenic demineralizing osteopathies].
Topics: Adrenal Cortex Hormones; Anticonvulsants; Female; Gonadotropin-Releasing Hormone; Humans; Iatrogenic | 1994 |
[Thyroid and osteoporosis].
Topics: Bone Density; Fractures, Spontaneous; Humans; Hyperthyroidism; Osteoporosis; Thyroxine | 1996 |
[The influence of thyroid diseases and their treatment on the development of osteoporosis].
Topics: Bone Density; Female; Humans; Male; Osteoporosis; Thyroid Diseases; Thyroxine | 1998 |
Conjugated estrogens--the natural SERMs.
Topics: 2-Methoxyestradiol; Anticarcinogenic Agents; Cardiovascular Diseases; Dihydrotestosterone; Equilin; | 1999 |
[The influence of thyrotoxicosis and thyroxine therapy on the risk of osteoporosis].
Topics: Bone Resorption; Female; Humans; Middle Aged; Osteoporosis; Thyroid Hormones; Thyrotoxicosis; Thyrox | 2000 |
Subclinical thyrotoxicosis.
Topics: Cardiovascular Diseases; Diagnosis, Differential; Disease Progression; Humans; Hyperthyroidism; Oste | 2001 |
Clinical practice. Subclinical hyperthyroidism.
Topics: Aged; Anticoagulants; Antithyroid Agents; Atrial Fibrillation; Female; Humans; Hyperthyroidism; Meth | 2001 |
[Osteoporosis in patients with thyroid disease].
Topics: Biomarkers; Bone Density; Bone Remodeling; Calcium; Diphosphonates; Estrogens; Humans; Hyperthyroidi | 2002 |
Endocrinology.
Topics: Adult; Diphosphonates; Endocrine System Diseases; Graves Disease; Growth Hormone; Humans; Hypercalce | 1991 |
Thyroxine replacement treatment and osteoporosis.
Topics: Female; Humans; Hypothyroidism; Male; Middle Aged; Osteoporosis; Thyroxine | 1990 |
Lumbar spine bone mineral content by photon beam absorptiometry. Methodology and application in osteoporosis.
Topics: Aging; Female; Fractures, Bone; Humans; Hyperthyroidism; Lumbar Vertebrae; Menopause; Methods; Miner | 1985 |
Effect of hormones on bone development.
Topics: Adolescent; Aging; Animals; Ascorbic Acid; Bone Development; Calcitonin; Calcium; Collagen; Diphosph | 1972 |
4 trials available for thyroxine and Osteoporosis
| Article | Year |
|---|---|
Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.
Topics: Age of Onset; Aged; Aged, 80 and over; Asymptomatic Diseases; Bone and Bones; Bone Density; Bone Rem | 2020 |
Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.
Topics: Age of Onset; Aged; Aged, 80 and over; Asymptomatic Diseases; Bone and Bones; Bone Density; Bone Rem | 2020 |
Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.
Topics: Age of Onset; Aged; Aged, 80 and over; Asymptomatic Diseases; Bone and Bones; Bone Density; Bone Rem | 2020 |
Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.
Topics: Age of Onset; Aged; Aged, 80 and over; Asymptomatic Diseases; Bone and Bones; Bone Density; Bone Rem | 2020 |
[Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine].
Topics: Aged; Bone Density; Female; Femur; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteopo | 2001 |
Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Bone Density; Bone Diseases, Metabolic; Carcinoma; Female; Femur Neck; Humans | 2005 |
Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Topics: Adult; Bone Density; Calcium; Dose-Response Relationship, Drug; Female; Goiter; Humans; Middle Aged; | 1994 |
72 other studies available for thyroxine and Osteoporosis
| Article | Year |
|---|---|
Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study.
Topics: Aged; Case-Control Studies; Female; Hormone Replacement Therapy; Humans; Osteoporosis; Saudi Arabia; | 2022 |
Evaluation of cortical and trabecular bone structure of the mandible in patients using L-Thyroxine.
Topics: Adolescent; Adult; Bone Density; Cancellous Bone; Case-Control Studies; Female; Humans; Male; Mandib | 2023 |
Thyroid-stimulating hormone decreases the risk of osteoporosis by regulating osteoblast proliferation and differentiation.
Topics: Adult; Animals; Animals, Newborn; Bone Density; Cell Differentiation; Cell Proliferation; Cells, Cul | 2021 |
Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Brazil; Cancellous Bone; C | 2021 |
Case report: fast reversal of severe osteoporosis after correction of excessive levothyroxine treatment and long-term follow-up.
Topics: Adult; Bone Density; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femoral | 2017 |
Glossodynia After Osteoporosis Treatment.
Topics: Aged; Denosumab; Female; Glossalgia; Hashimoto Disease; Humans; Osteoporosis; Thyroxine | 2017 |
Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study.
Topics: Humans; Incidence; Osteoporosis; Retrospective Studies; Risk Factors; Taiwan; Thyroid Neoplasms; Thy | 2018 |
Evaluation of Bone Mineral Density Using DXA and cQCT in Postmenopausal Patients Under Thyrotropin Suppressive Therapy.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Cross-Sectional Studies; Female; Hum | 2018 |
Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women.
Topics: Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Female; Fractures, Bone; Humans; Hypoth | 2014 |
Assessment of bone mineral density in patients with Sheehan's syndrome.
Topics: Absorptiometry, Photon; Adrenocorticotropic Hormone; Bone Density; Case-Control Studies; Estradiol; | 2014 |
Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?
Topics: Bone and Bones; Bone Density Conservation Agents; Combined Modality Therapy; Dose-Response Relations | 2014 |
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
Topics: Adult; Aged; Bone and Bones; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle | 2015 |
Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Topics: Aged; Atrial Fibrillation; Bone Diseases; Cardiovascular Diseases; Female; Humans; Hyperthyroidism; | 2015 |
Evaluation of thyroid function status among postmenopausal women with and without osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Case-Control Studies; Female; Humans; Logistic Models; Lumbar | 2016 |
Thyroid Function and its Implications in Oxidative Stress Influencing the Pathogenesis of Osteoporosis in Adults with Down Syndrome: A Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antioxidants; Bone Density; Cohort Studies; Down Syndrom | 2016 |
Sheep model for osteoporosis: The effects of peripheral hormone therapy on centrally induced systemic bone loss in an osteoporotic sheep model.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Resorption; Disease Models, Ani | 2017 |
Atypical thyrotropin-secreting pituitary microadenoma revealed by severe osteoporosis in a young man.
Topics: Adult; Alkaline Phosphatase; Body Height; Body Weight; Bone Density; Calcium; Carbimazole; Diphospho | 2009 |
Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Cross-Sectional Studies; Female; Forearm; Humans; | 2009 |
[Osteoporosis--current diagnostics and therapy].
Topics: Absorptiometry, Photon; Accidental Falls; Bone Density; Bone Density Conservation Agents; Calcium; C | 2009 |
Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Comorbidity; Female; Fractures, | 2010 |
[Pharmaceutical care of an osteoporosis patient with hypothyroidism].
Topics: Absorptiometry, Photon; Aged, 80 and over; Bone Density Conservation Agents; Combined Modality Thera | 2009 |
The association between serum thyrotropin (TSH) levels and bone mineral density in healthy euthyroid men.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; | 2010 |
[Clinical endocrinologists' perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma].
Topics: Adult; Attitude of Health Personnel; Carcinoma; Cognition Disorders; Cross-Sectional Studies; Data C | 2010 |
A case of myxedema coma caused by isolated thyrotropin stimulating hormone deficiency and Hashimoto's thyroiditis.
Topics: Autoantibodies; Carcinoembryonic Antigen; Cardiomegaly; Coma; Female; Hashimoto Disease; Human Growt | 2011 |
Severe postpartum osteoporosis with increased PTHrP during lactation in a patient after total thyroidectomy and parathyroidectomy.
Topics: Absorptiometry, Photon; Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remo | 2011 |
Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Calcium; Crea | 2011 |
A large-scale population-based analysis of common genetic variation in the thyroid hormone receptor alpha locus and bone.
Topics: Bone and Bones; Bone Density; Fractures, Bone; Genetic Loci; Genetic Variation; Humans; Nuclear Rece | 2012 |
Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Dose-Response Relationship, Drug; | 2012 |
[HYPOCALCIURIC EFFECT OF BENZTHIAZIDE].
Topics: Benzothiadiazines; Calcium; Calcium Metabolism Disorders; Calcium, Dietary; Diuretics; Geriatrics; H | 1963 |
HORMONAL DISTURBANCES IN THE ELDERLY.
Topics: Aged; Aging; Androgens; Calcium; Calcium, Dietary; Diethylstilbestrol; Endocrinology; Erectile Dysfu | 1964 |
Effects of osteoporotic cytokines in ovary-intact and ovariectomised rats with induced hyperthyroidism; is skeletal responsiveness to thyroid hormone altered in estrogen deficiency?
Topics: Animals; Bone and Bones; Calcium; Cytokines; Estrogens; Female; Hyperthyroidism; Osteoporosis; Ovari | 2003 |
Osteoporotic cytokines and bone metabolism on rats with induced hyperthyroidism; changes as a result of reversal to euthyroidism.
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Calcium; Cytokines; Female; Hyperthyroidism; Interleu | 2003 |
Prevention of bone loss in ovariectomized rats: the effect of Salvia miltiorrhiza extracts.
Topics: Alkaline Phosphatase; Animals; Calcium; Cell Count; Compressive Strength; Female; Femur; Osteoclasts | 2004 |
Effect of dang-gui-ji-hwang-yeum on osteoporosis in ovariectomized rats.
Topics: Angelica sinensis; Animals; Drugs, Chinese Herbal; Female; Femur; Microscopy; Osteoblasts; Osteoclas | 2004 |
Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma.
Topics: Absorptiometry, Photon; Adult; Aged; Biomarkers; Bone Density; Cell Differentiation; Cross-Sectional | 2005 |
New questions regarding bioequivalence of levothyroxine preparations: a clinician's response.
Topics: Area Under Curve; Atrial Fibrillation; Biological Availability; Biopharmaceutics; Chemistry, Pharmac | 2005 |
I have an underactive thyroid and take the thyroid drug levothyroxine. I also take a calcium supplement to help prevent osteoporosis. I've heard that I should take these two at different times of the day. Is this true?
Topics: Calcium; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypothyroidism; Osteoporos | 2005 |
[Features of osteopenic syndrome in diffuse toxic goiter].
Topics: Adult; Aged; Bone Density; Bone Diseases, Metabolic; Calcium; Case-Control Studies; Densitometry; Fe | 2005 |
Bone mineral density in bulimic women--influence of endocrine factors and previous anorexia.
Topics: Absorptiometry, Photon; Adult; Anorexia Nervosa; Bone Density; Bulimia; Cross-Sectional Studies; Est | 2006 |
Thyroid hormone-induced demineralisation of the vertebral skeleton of the eel, Anguilla anguilla.
Topics: Anguilla; Animals; Bone Demineralization, Pathologic; Bone Density; Bone Resorption; Female; Osteopo | 2007 |
Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.
Topics: Alkaline Phosphatase; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Cell Different | 2007 |
Bone metabolism in ovariectomized rats with induced hyperthyroidism: the effect of estrogen replacement.
Topics: Animals; Bone and Bones; Estrogen Replacement Therapy; Estrogens; Female; Hyperthyroidism; Interleuk | 2006 |
Modeling the effect of levothyroxine therapy on bone mass density in postmenopausal women: a different approach leads to new inference.
Topics: Aged; Bone Density; Female; Humans; Middle Aged; Osteoporosis; Postmenopause; Thyroxine | 2007 |
Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss.
Topics: Animals; Bone Density; Cell Differentiation; Cells, Cultured; Female; Humans; Injections; Mice; Oste | 2008 |
Levothyroxine therapy and osteoporosis. An end to the controversy?
Topics: Bone Density; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Thyroxine | 1995 |
Detrimental skeletal effects of thyrotropin suppressive doses of thyroxine: fact or fantasy?
Topics: Bone and Bones; Bone Density; Dose-Response Relationship, Drug; Humans; Osteoporosis; Risk Factors; | 1994 |
Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.
Topics: Absorptiometry, Photon; Adenocarcinoma, Follicular; Adult; Age Factors; Aged; Bone Density; Carcinom | 1993 |
Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messenger ribonucleic acid markers of osteoblast and osteoclast function.
Topics: Animals; Biomarkers; Bone Density; Etidronic Acid; Femur; Male; Osteoblasts; Osteoclasts; Osteoporos | 1993 |
Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Topics: Adult; Aged; Bone Density; Cross-Sectional Studies; Female; Femur Neck; Goiter, Nodular; Humans; Hyp | 1993 |
Therapeutic success in severe iatrogenic osteoporosis in a young woman.
Topics: Adult; Antineoplastic Agents; Female; Humans; Iatrogenic Disease; Lumbar Vertebrae; Osteoporosis; Ra | 1993 |
Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Carcinoma; Case-Control Studies; Female; Hip; Humans; | 1996 |
Feasibility of reducing L-thyroxine dose in patients with a suppressed serum TSH.
Topics: Feasibility Studies; Follow-Up Studies; Humans; Osteoporosis; Registries; Thyrotropin; Thyroxine | 1995 |
Bone mineral density and L-thyroxine treatment in rapidly cycling bipolar disorder.
Topics: Adult; Bipolar Disorder; Bone Density; Cross-Sectional Studies; Female; Humans; Menopause; Middle Ag | 1997 |
An ectopic parathyroid adenoma revealed by L-thyroxine side effect on bone. Case report.
Topics: Adenoma; Aged; Female; Humans; Hyperparathyroidism; Osteoporosis; Parathyroid Neoplasms; Thyroid Gla | 1997 |
[Post-thyroidectomy osteoporosis].
Topics: Adult; Bone Density; Calcitonin; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Male; Midd | 1996 |
Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Topics: Adult; Body Mass Index; Bone Density; Female; Goiter; Humans; Hyperthyroidism; Linear Models; Middle | 1998 |
[Olpadronate prevents cortical and trabecular bone loss induced by supraphysiological dosis of thyroxine in ovariectomized rats].
Topics: Animals; Bone Density; Diphosphonates; Female; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley | 1998 |
Simulated weightlessness-induced attenuation of testosterone production may be responsible for bone loss.
Topics: Animals; Bone Density; Calcitriol; Corticosterone; Femur; Hindlimb; Hydrocortisone; Male; Organ Size | 1999 |
[Diagnosis of short-term subclinical shifts in the level of humoral parameters].
Topics: Adult; Algorithms; Female; Hormones; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Models, The | 2000 |
Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Neoplasms; Collagen; Collagen Type | 2001 |
Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Topics: Adult; Biomarkers; Bone Density; Calcium; Combined Modality Therapy; Croatia; Female; Humans; Long-T | 2001 |
[Current trends in the treatment of common osteoporosis].
Topics: Adult; Aged; Calcitonin; Calcium; Diphosphonates; Estrogens; Fluorides; Humans; Middle Aged; Osteopo | 1977 |
Long-term thyroxine treatment and bone mineral density.
Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Body Mass Index; Bone Density; Calcium; C | 1992 |
[Can substitution therapy with thyroxine cause osteoporosis?].
Topics: Humans; Hypothyroidism; Osteoporosis; Thyroxine | 1992 |
[Experimental study of thyroid hormone and bone metabolism in the rat].
Topics: Animals; Bone and Bones; Bone Density; Calcitonin; Female; Osteoporosis; Parathyroid Glands; Rats; T | 1990 |
Thyroxine, osteoporosis and fractures in the mentally handicapped.
Topics: Adult; Aged; Aged, 80 and over; Female; Fractures, Spontaneous; Humans; Hypothyroidism; Intellectual | 1990 |
Thyroxine replacement treatment and osteoporosis.
Topics: Female; Humans; Hypothyroidism; Osteoporosis; Thyroxine | 1990 |
Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Bone and Bones; Bromocriptine; Female; Gonadal Steroid Hormones; Gonado | 1988 |
Osteoporosis and fractures following thyrotoxicosis.
Topics: Age Factors; Aged; Calcium; Densitometry; Female; Fractures, Bone; Humans; Hyperthyroidism; Iodine I | 1971 |
Letter: Replacement treatment of hypothyroidism.
Topics: Female; Humans; Hyperthyroidism; Hypothyroidism; Menopause; Osteoporosis; Thyroid Hormones; Thyrotro | 1974 |
[Iodinated thyroid hormones and phosphocalcic metabolism].
Topics: Bone Diseases; Calcitonin; Calcium; Calcium Metabolism Disorders; Humans; Hypercalcemia; Hyperthyroi | 1971 |
[Diagnosis and therapy of the secondary disease: geriatrics].
Topics: Aged; Central Nervous System Diseases; Cerebrovascular Disorders; Cortisone; Diabetes Mellitus; Digi | 1973 |